Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer

被引:4
作者
Graeser, M. [1 ]
Bosse, K. [1 ]
Brosig, M. [2 ]
Engel, C. [2 ]
Schmutzler, R. K. [1 ]
机构
[1] Univ Hosp Cologne, Dept Gynecol & Obstet, Ctr Familial Breast & Ovarian Canc, D-50931 Cologne, Germany
[2] Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany
关键词
BRCA1; Breast cancer; Estrogen receptor; Progesterone receptor; BRCA1; ESTROGEN; CARRIERS; OOPHORECTOMY; TAMOXIFEN; RISK;
D O I
10.1007/s00428-009-0760-8
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
BRCA1-associated breast cancer frequently presents with estrogen-receptor (ER alpha) and progesterone-receptor (PR) negativity, grade 3, and early onset. In contrast, in BRCA1-deficient mice, ER alpha is highly expressed in early tumorigenesis. In a retrospective cohort study on 587 breast cancer patients with deleterious BRCA1 mutations, the correlation of ER, PR status, grading, age of onset, and tumor size was investigated. ER alpha and PR expression decreased from 62% in ductal carcinoma in situ (DCIS) to 20% and 16% in pT3, respectively (p value for ER 0.025 and PR 0.035, Fisher's exact test). The percentage of grade 1/2 tumors decreased from 44% in DCIS to 17% in pT3 (p value 0.074). Moreover, ER/PR positivity increased with increasing age. Our data suggest that early stage BRCA1-associated breast cancers are more frequently ER alpha and PR positive and low grade than advanced stages.
引用
收藏
页码:519 / 524
页数:6
相关论文
共 25 条
  • [1] Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer
    Atchley, Deann P.
    Albarracin, Constance T.
    Lopez, Adriana
    Valero, Vicente
    Amos, Christopher I.
    Gonzalez-Angulo, Ana Maria
    Hortobagyi, Gabriel N.
    Arun, Banu K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) : 4282 - 4288
  • [2] EISINGER F, 1999, CANCER, V1585, P2291
  • [3] BRCA1 inhibition of estrogen receptor signaling in transfected cells
    Fan, S
    Wang, JA
    Yuan, R
    Ma, Y
    Meng, Q
    Erdos, MR
    Pestell, RG
    Yuan, F
    Auborn, KJ
    Goldberg, ID
    Rosen, EM
    [J]. SCIENCE, 1999, 284 (5418) : 1354 - 1356
  • [4] Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
    Ford, D
    Easton, DF
    Stratton, M
    Narod, S
    Goldgar, D
    Devilee, P
    Bishop, DT
    Weber, B
    Lenoir, G
    Chang-Claude, J
    Sobol, H
    Teare, MD
    Struewing, J
    Arason, A
    Scherneck, S
    Peto, J
    Rebbeck, TR
    Tonin, P
    Neuhausen, S
    Barkardottir, R
    Eyfjord, J
    Lynch, H
    Ponder, BAJ
    Gayther, SA
    Birch, JM
    Lindblom, A
    Stoppa-Lyonnet, D
    Bignon, Y
    Borg, A
    Hamann, U
    Haites, N
    Scott, RJ
    Maugard, CM
    Vasen, H
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) : 676 - 689
  • [5] RISKS OF CANCER IN BRCA1-MUTATION CARRIERS
    FORD, D
    EASTON, DF
    BISHOP, DT
    NAROD, SA
    GOLDGAR, DE
    HAITES, N
    MILNER, B
    ALLAN, L
    PONDER, BAJ
    PETO, J
    SMITH, S
    STRATTON, M
    LENOIR, GM
    FEUNTEUN, J
    LYNCH, H
    ARASON, A
    BARKARDOTTIR, R
    EGILSSON, V
    BLACK, DM
    KELSELL, D
    SPURR, N
    DEVILEE, P
    CORNELISSE, CJ
    VARSEN, H
    BIRCH, JM
    SKOLNICK, M
    SANTIBANEZKOREF, MS
    TEARE, D
    STEEL, M
    PORTER, D
    COHEN, BB
    CAROTHERS, A
    SMYTH, E
    WEBER, B
    NEWBOLD, B
    BOEHNKE, M
    COLLINS, FS
    CANNONALBRIGHT, LA
    GOLDGAR, D
    [J]. LANCET, 1994, 343 (8899) : 692 - 695
  • [6] Estrogen receptor status in BRCA1- and BRCA2-related breast cancer:: The influence of age, grade, and histological type
    Foulkes, WD
    Metcalfe, K
    Sun, P
    Hanna, WM
    Lynch, HT
    Ghadirian, P
    Tung, N
    Olopade, OI
    Weber, BL
    McLennan, J
    Olivotto, IA
    Bégin, LR
    Narod, SA
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (06) : 2029 - 2034
  • [7] Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population
    Hofmann, W
    Scherneck, S
    Horn, D
    Paepke, S
    Grumann, M
    Wappenschmidt, B
    Kempe, A
    Friedl, W
    von der Groeben, C
    Schmutzler, RK
    Betz, B
    Goecke, TO
    Bodden-Heidrich, R
    Beckmann, MW
    Niederacher, D
    Krueger, M
    Schaefer, D
    Jordan, J
    von Minckwitz, G
    Arnemann, J
    Botz, J
    Bartram, CR
    Voigtländer, T
    Bastert, G
    Henningsen, P
    Arnold, NK
    Gross, E
    Schlegelberger, B
    Gerber, WD
    Kiechle, M
    Thamm, B
    Kraus, H
    Langanke, D
    Voigt, T
    Froster, UG
    Brandau, O
    Golla, A
    Vodermeier, A
    Nestle-Krämling, C
    Meindl, A
    Preisler-Adams, S
    Dwornic-zak, B
    Jebali, P
    Jakisch, C
    Horst, J
    Eberhardt, E
    Volm, T
    Bochum, S
    Tamulionyte, L
    Grill, HJ
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (04) : 472 - 480
  • [8] Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8
  • [9] Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer
    Jones L.P.
    Li M.
    Halama E.D.
    Ma Y.
    Lubet R.
    Grubbs C.J.
    Deng C.-X.
    Rosen E.M.
    Furth P.A.
    [J]. Oncogene, 2005, 24 (22) : 3554 - 3562
  • [10] Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff, ND
    Satagopan, JM
    Robson, ME
    Scheuer, L
    Hensley, M
    Hudis, CA
    Ellis, NA
    Boyd, J
    Borgen, PI
    Barakat, RR
    Norton, L
    Offit, K
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (21) : 1609 - 1615